Vita Balance PLUS+ Bacterial Cultures - 33 Vegan Lemon Shots - 500ml

Vita Balance PLUS+ Bacterial Cultures - 33 Vegan Lemon Shots - 500ml

CHF 24.99
Sale price  CHF 24.99 Regular price 
Skip to product information
Vita Balance PLUS+ Bacterial Cultures - 33 Vegan Lemon Shots - 500ml

Vita Balance PLUS+ Bacterial Cultures - 33 Vegan Lemon Shots - 500ml

CHF 24.99
Sale price  CHF 24.99 Regular price 

Highly concentrated probiotic in liquid shot form – for maximum bioavailability of bacterial cultures. The gut microbiome regulates endogenous GLP-1 production: certain bacterial strains stimulate the body's own GLP-1 secretion from the L-cells of the gut – synergistic with GLP-1 therapy.

Benefits: Promotes endogenous GLP-1 production · Improves gut microbiome diversity · Supports immune system and digestion · Liquid format for highest bioavailability

Shipped from Germany · Vegan ✓ · No added sugar ✓ · Non-GMO ✓ · HACCP compliant · GMP certified · ISO 22000 · Halal certified


Scientific Background – Based on publicly available research literature. For general information only and not a substitute for medical advice.

  • Gut Microbiome and Endogenous GLP-1: Intestinal L-cells – primarily located in the ileum and colon – produce endogenous GLP-1. Certain gut bacterial strains stimulate this secretion via short-chain fatty acids (SCFAs), especially butyrate and propionate, which act as L-cell secretagogues.
  • Akkermansia muciniphila: This mucin-degrading strain is associated with improved metabolic parameters and increased GLP-1 secretion (Plovier et al., Nature Medicine, 2017). Clinical human studies show improvements in insulin sensitivity and inflammatory markers.
  • Liquid Format & Bioavailability: Liquid probiotics, when properly buffered (e.g., slightly alkaline environment), can exhibit a higher survival rate of bacterial cultures until gut colonization than unbuffered dry capsules, as the stomach passage is less destructive.
  • Strain Specificity: Probiotic effects are strictly strain-specific – statements about one strain do not automatically apply to other strains of the same species (e.g., L. rhamnosus GG vs. other L. rhamnosus strains).
  • EFSA Status: The EFSA has not yet approved specific health claims for probiotics; evidence of efficacy is considered strain-specific and dose-dependent.

You may also like